Publications

Below is a selection of publications on PentraSorb^® CRP and the pathological effects of CRP.

• Blood Purif. 2020 Feb 28:1-5. doi: 10.1159/000506176.
  A Promising Innovative Treatment for ST-Elevation Myocardial Infarction: The Use of C-Reactive Protein Selective Apheresis: Case Report
  Boljevic D, Nikolic A, Rusovic S, Lakcevic J, Bojic M, Balint B.
  
• Ther Apher Dial. 2019 Dec;23(6):494-496. doi: 10.1111/1744-9987.12802.
  C-Reactive Protein: From Biomarker to Trigger of Cell Death?
  Kunze, R.
  
• Ther Apher Dial. 2019 Dec;23(6):570-574. doi: 10.1111/1744-9987.12804. Epub 2019 Apr 29.
  Selective C-Reactive Protein Apheresis in Patients.
  Ries W, Heigl F, Garlichs C, Sheriff A, Torzewski J.
  
• Nephro News. Issue 6/2019; Year 21: 23-27.
  CRP apheresis: A new treatment option for inflammation.
  Ries W.
  Publication courtesy of Medicom VerlagsgmbH
  
• Ther Apher Dial. 2019 Oct;23(5):474-481. doi: 10.1111/1744-9987.12796. Epub 2019 Mar 21.
  PentraSorb C-Reactive Protein: Characterization of the Selective C-Reactive Protein Adsorber Resin.
  Mattecka S, Brunner P, Hähnel B, Kunze R, Vogt B, Sheriff A.
  
• Case Rep Cardiol. 2018 Nov 6;2018:4767105. doi: 10.1155/2018/4767105. eCollection 2018.
  “First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute
  ST Segment Elevation Myocardial Infarction.
  Ries W, Sheriff A, Heigl F, Zimmermann O, Garlichs CD, Torzewski J.
  
• Arch Med Sci. 2017 Aug;13(5):1086-1093. doi: 10.5114/aoms.2017.69327. Epub 2017 Aug 3.
  C-reactive protein levels predict systolic heart failure and outcome in patients with first
  ST-elevation myocardial infarction treated with coronary angioplasty.
  Stumpf C, Sheriff A, Zimmermann S, Schaefauer L, Schlundt C, Raaz D, Garlichs CD, Achenbach S.
  
• J Clin Apher. 2015 Feb;30(1):15-21. doi: 10.1002/jca.21344. Epub 2014 Jul 5.
  Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction?
  Sheriff A, Schindler R, Vogt B, Abdel-Aty H, Unger JK, Bock C, Gebauer F, Slagman A, Jerichow T, Mans D, Yapici G, Janelt G, Schröder M, Kunze R, Möckel M.
  
• Blood Purif. 2011;31(1-3):9-17. doi: 10.1159/000320763. Epub 2010 Dec 7.
  Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model.
  Slagman AC, Bock C, Abdel-Aty H, Vogt B, Gebauer F, Janelt G, Wohlgemuth F, Morgenstern R, Yapici G, Puppe A, Modersohn D, Mans D, Jerichow T, Ott S, Kunze R, Schrödl W, Janko C, Hermann M, Kalden JR, Kern P, Parsch H, Kirschfink M, Schulz-Menger J, Röttgen R, Unger JK, Frei U, Schindler R, Möckel M, Sheriff A.
  
• N Engl J Med. 2006 Aug 3;355(5):513-5.
  Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein.
  Kitsis RN, Jialal I
• Nature. 2006 Apr 27;440(7088):1217-21.
  Targeting C-reactive protein for the treatment of cardiovascular disease.
  Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP.
  
• J Cereb Blood Flow Metab. 2004 Nov;24(11):1214-8.
  Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.
  Gill R, Kemp YES, Sabin C, Pepys MB.
  
• J Pharmacol Exp Ther. 2002 Dec;303(3):1007-13.
  C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion.
  Barrett TD, Hennan JK, Marks RM, Lucchesi BR.
  
• J Exp Med. 1999 Dec 20;190(12):1733-40.
  C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.
  Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB.